Navigation Links
MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
Date:1/18/2011

WARREN, N.J., Jan. 18, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, filed an amended patent infringement and false marking lawsuit today against BioDelivery Sciences International, Inc. (NASDAQ: BDSI; "BDSI"), MEDA Pharmaceuticals Inc. ("MEDA"), and Aveva Drug Delivery Systems, Inc. ("Aveva") in the United States District Court for the District of New Jersey.

MonoSol Rx's complaint asserts that BDSI, MEDA, and Aveva's manufacture, marketing, and sale of the Onsolis™ film products infringe MonoSol Rx's United States Patent No. 7,824,588 related to methods of making drug-containing films.  As one of the leaders in the development and commercialization of film pharmaceutical and over-the-counter drug products, MonoSol Rx has an extensive technology patent portfolio.

MonoSol Rx filed its patent infringement claim against these defendants initially in November, 2010.  Today's amended complaint adds an additional false marking claim with respect to U.S. Patent No. 5,800,832.

MonoSol Rx is represented in the action by Howrey LLP.

About MonoSol Rx MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator or other specialty pharma companies that can sell-in and manage product sales and marketing.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).For existing and future partners, PharmFilm® formulations can also represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.
For press releases and other company information visit www.monosolrx.com Contacts:MonoSol RxKeith Kendall, Executive Vice President(732) 564-5000The Ruth Group
(on behalf of MonoSol Rx)Jason Rando (media)Tel: +1 (646) 536-7025jrando@theruthgroup.com  Sara Pellegrino (investors)Tel: +1 (646) 536-7002spellegrino@theruthgroup.com  
'/>"/>

SOURCE MonoSol Rx, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
4. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
5. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
6. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
7. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. ERT Files Shelf Registration Statement
11. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have ... from Pixel Film Studios. With ProSharpen Color users have total control over sharpening amount, ... their color range. With color spectrum tools users can visually see the color range ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces the ... body image mannequin art competition. Selected from 15 submissions from around the nation, the ... the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This ...
Breaking Medicine News(10 mins):